Evidence map›Paper›PMID 40866758›Full record

ArticleBreast cancer research and treatment2025

Beyond the 5-year mark: adherence to and continuation of extended adjuvant endocrine therapy in non-metastatic breast cancer patients.

Jenny Wei, Ashley Aller, Shiyun Zhu, Laurel A Habel, Catherine Lee, Jun Shan, Ninah Achacoso, Aida Shirazi, Marc A Emerson, Raymond Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jenny WeiDepartment of Hematology and Oncology, Kaiser Permanente Northern California, 2238 Geary Boulevard, 8th Floor SE, San Francisco, CA, 94115, USA. Jenny.X1.Wei@kp.org.ORCID http://orcid.org/0000-0001-5572-7205
Ashley AllerDepartment of Hematology and Oncology, Northwest Medical Specialties, Tacoma, WA, USA.
Shiyun ZhuDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Laurel A HabelDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Catherine LeeDivision of Biostatistics, University of California San Francisco, San Francisco, CA, USA.
Jun ShanDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Ninah AchacosoDivision of Research, Kaiser Permanente Northern California, Pleasanton, CA, USA.
Aida ShiraziDepartment of Graduate Medical Education, Kaiser Permanente Northern California, San Francisco, CA, USA.
Marc A EmersonDepartment of Epidemiology, University of North Carolina, Chapel Hill, NC, USA.
Raymond LiuDepartment of Hematology and Oncology, Kaiser Permanente Northern California, 2238 Geary Boulevard, 8th Floor SE, San Francisco, CA, 94115, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeExtended adjuvant endocrine therapy (AET) beyond 5 years (up to 10 years) has been shown to be beneficial for some women with non-metastatic, hormone-receptor positive breast cancer. Much of our current understanding of adherence to and continuation with AET is derived from examining the 5 years after AET initiation and is limited beyond the first 5 years. To address this limitation, we conducted a retrospective cohort study examining AET adherence and time of continuation beyond 5 years among a large, real-world population in Northern California.

methodsWe evaluated adherence to and continuation of extended AET among a cohort of 13,675 women diagnosed with Stage I-III, estrogen receptor positive (ER+) breast cancer between 2008 and 2017 treated at Kaiser Permanente Northern California. Adherence (medication possession ratio > 80%) and discontinuation (last pill possession date before a 180-day gap) of AET were examined.

resultsAnnual AET adherence declined gradually each year from 79% in year 1-60% in year 5 and dropped dramatically to 23% in year 6. Following year 6, annual adherence again declined gradually and was 10% in year 10. Similarly, there was a striking decline in AET continuation between year 5 (52%) and year 6 (20%). Only 4.5% continued to the end of year 10.

conclusionsWe observed a dramatic drop in both adherence to and continuation with AET following year 5 into year 6. This potentially represents an inflection point for intervention to improve adherence to and continuation with extended AET among this patient population.

Indexed as

Antineoplastic Agents, HormonalBreast NeoplasmsMedication AdherenceAdultAgedAged, 80 and overCaliforniaChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoplasm StagingReceptors, EstrogenRetrospective StudiesAntineoplastic Agents, HormonalReceptors, EstrogenAdjuvant drug therapyAdjuvant endocrine therapyBreast neoplasmMedication adherenceMedication continuation

Identifiers

PMID40866758

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.